Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.

Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, Guery B, Dervaux B.

PLoS One. 2017 Jan 19;12(1):e0170258. doi: 10.1371/journal.pone.0170258. eCollection 2017.

2.

Natural products as mediators of disease.

Garg N, Luzzatto-Knaan T, Melnik AV, Caraballo-Rodríguez AM, Floros DJ, Petras D, Gregor R, Dorrestein PC, Phelan VV.

Nat Prod Rep. 2017 Feb 1;34(2):194-219. doi: 10.1039/c6np00063k. Epub 2016 Nov 22.

PMID:
27874907
3.

Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2016 Jul 1;16(17):1-69. eCollection 2016. Review.

4.

Fecal Microbiota Transplantation: A Review of Emerging Indications Beyond Relapsing Clostridium difficile Toxin Colitis.

Jung Lee W, Lattimer LD, Stephen S, Borum ML, Doman DB.

Gastroenterol Hepatol (N Y). 2015 Jan;11(1):24-32.

5.

Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, Hota S.

PLoS One. 2016 Feb 22;11(2):e0149521. doi: 10.1371/journal.pone.0149521. eCollection 2016.

6.

Colonization potential to reconstitute a microbe community in patients detected early after fecal microbe transplant for recurrent C. difficile.

Kumar R, Maynard CL, Eipers P, Goldsmith KT, Ptacek T, Grubbs JA, Dixon P, Howard D, Crossman DK, Crowley MR, Benjamin WH Jr, Lefkowitz EJ, Weaver CT, Rodriguez JM, Morrow CD.

BMC Microbiol. 2016 Jan 13;16:5. doi: 10.1186/s12866-015-0622-2.

7.

Fecal microbiota transplantation: current clinical efficacy and future prospects.

Bowman KA, Broussard EK, Surawicz CM.

Clin Exp Gastroenterol. 2015 Oct 23;8:285-91. doi: 10.2147/CEG.S61305. eCollection 2015. Review.

8.

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook.

Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G.

Gastroenterology. 2015 Jul;149(1):223-37. doi: 10.1053/j.gastro.2015.05.008. Epub 2015 May 15. Review.

9.

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review.

Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, Ponsioen CY.

World J Gastroenterol. 2015 May 7;21(17):5359-71. doi: 10.3748/wjg.v21.i17.5359. Review.

10.

Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection.

Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G.

BMC Infect Dis. 2015 Apr 17;15:191. doi: 10.1186/s12879-015-0930-z.

11.

Harnessing regulatory T cells for the treatment of inflammatory bowel disease.

Geem D, Harusato A, Flannigan K, Denning TL.

Inflamm Bowel Dis. 2015 Jun;21(6):1409-18. doi: 10.1097/MIB.0000000000000343. Review.

12.

Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection.

Allegretti JR, Korzenik JR, Hamilton MJ.

J Vis Exp. 2014 Dec 8;(94). doi: 10.3791/52154.

13.

Clostridium difficile infection: guideline-based diagnosis and treatment.

Lübbert C, John E, von Müller L.

Dtsch Arztebl Int. 2014 Oct 24;111(43):723-31. doi: 10.3238/arztebl.2014.0723. Review.

14.

Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease.

Aroniadis OC, Brandt LJ.

Gastroenterol Hepatol (N Y). 2014 Apr;10(4):230-7.

15.

Chemoprevention in gastrointestinal physiology and disease. Natural products and microbiome.

Greiner AK, Papineni RV, Umar S.

Am J Physiol Gastrointest Liver Physiol. 2014 Jul 1;307(1):G1-15. doi: 10.1152/ajpgi.00044.2014. Epub 2014 May 1. Review.

16.

Restoring the gut microbiome for the treatment of inflammatory bowel diseases.

Allegretti JR, Hamilton MJ.

World J Gastroenterol. 2014 Apr 7;20(13):3468-74. doi: 10.3748/wjg.v20.i13.3468. Review.

17.

Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.

Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN.

Clin Infect Dis. 2014 Jun;58(11):1507-14. doi: 10.1093/cid/ciu128. Epub 2014 Mar 31.

18.

Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercoe E.

Microbiome. 2013 Jan 9;1(1):3. doi: 10.1186/2049-2618-1-3.

19.

Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation.

Pathak R, Enuh HA, Patel A, Wickremesinghe P.

Clin Exp Gastroenterol. 2013 Dec 27;7:1-6. doi: 10.2147/CEG.S53410. eCollection 2013.

20.

Metabiotics: novel idea or natural development of probiotic conception.

Shenderov BA.

Microb Ecol Health Dis. 2013 Apr 12;24. doi: 10.3402/mehd.v24i0.20399. eCollection 2013.

Supplemental Content

Support Center